Exact Sciences (EXAS) Set to Announce Quarterly Earnings on Wednesday

Exact Sciences (NASDAQ:EXAS) is scheduled to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect Exact Sciences to post earnings of ($0.50) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.26. The firm had revenue of $646.89 million during the quarter, compared to analyst estimates of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The business’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.72) EPS. On average, analysts expect Exact Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Exact Sciences Stock Up 2.5 %

NASDAQ:EXAS opened at $62.07 on Monday. The company has a quick ratio of 2.07, a current ratio of 2.32 and a debt-to-equity ratio of 0.74. Exact Sciences has a 12-month low of $56.05 and a 12-month high of $100.77. The stock’s fifty day simple moving average is $63.37 and its 200-day simple moving average is $64.72. The firm has a market capitalization of $11.41 billion, a P/E ratio of -54.45 and a beta of 1.26.

Insider Buying and Selling

In related news, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total transaction of $69,473.25. Following the transaction, the chief executive officer now directly owns 1,156,191 shares in the company, valued at $69,544,888.65. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Kevin T. Conroy sold 1,155 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the sale, the chief executive officer now directly owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James Herriott sold 421 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $25,862.03. Following the transaction, the general counsel now directly owns 6,494 shares in the company, valued at approximately $398,926.42. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 70,611 shares of company stock worth $4,255,377. Corporate insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on EXAS shares. William Blair restated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. Citigroup reissued a “buy” rating and issued a $100.00 price target on shares of Exact Sciences in a report on Wednesday, April 3rd. Finally, Canaccord Genuity Group lowered their price objective on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.07.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.